4D Molecular Therapeutics, Inc. Liquidation Value

FDMT Other

Cash & Equivalents

$60.24M
As of 2025-12-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $60.24M
Total Obligations: -$65.40M
$-5.16M
Per share: $-0.09
Period: 2025-12-31

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $60.24M
AR: $0
Total Obligations: -$65.40M
$-5.16M
Per share: $-0.09
Period: 2025-12-31

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $60.24M
AR: $0
Inventory: $0
Total Obligations: -$65.40M
$-5.16M
Per share: $-0.09
Period: 2025-12-31

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-5.16M$-0.09
Liquid Liquidation Value$-5.16M$-0.09
Operating Liquidation Value$-5.16M$-0.09

Key Components (as of 2025-12-31)

Cash & Equivalents$60.24M
Accounts ReceivableN/A
InventoryN/A
Current Liabilities$43.98M
Long-term DebtN/A
Op. Lease Liability$21.41M
Finance LeaseN/A
Shares Outstanding57.6M

Explore all 163 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2025-12-31$60.24MN/AN/A$11.16M$43.98MN/A$21.41MN/A
2025-09-30$48.55MN/AN/A$6.86M$37.11MN/A$22.26MN/A
2025-06-30$77.16MN/AN/A$8.70M$34.68MN/A$23.08MN/A
2025-03-31$133.53MN/AN/A$4.15M$26.90MN/A$23.85MN/A
2024-12-31$149.34MN/AN/A$4.39M$29.15MN/A$24.61MN/A
2024-09-30$187.54MN/AN/A$2.92M$29.46MN/A$24.83MN/A
2024-06-30$189.06MN/AN/A$3.43M$19.40MN/A$13.66MN/A
2024-03-31$275.59MN/AN/A$4.22M$16.40MN/A$14.17MN/A

Comments

SEC Filings

PeriodFormFiledLink
2025-12-31 10-K 2026-03-18 View
2025-09-30 10-Q 2025-11-10 View
2025-06-30 10-Q 2025-08-11 View
2025-03-31 10-Q 2025-05-08 View
2024-12-31 10-K 2025-02-28 View
2024-09-30 10-Q 2024-11-13 View
2024-06-30 10-Q 2024-08-08 View
2024-03-31 10-Q 2024-05-09 View

Community Notes

Loading notes...

Questions

Loading questions...